Urogen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $33.00 target price on the stock. D. Boral Capital’s target price indicates a potential upside of 94.12% from the company’s previous close.

A number of other research firms have also commented on URGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Urogen Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

Urogen Pharma Stock Down 1.0%

Shares of Urogen Pharma stock opened at $17.00 on Tuesday. The company’s fifty day simple moving average is $19.84 and its two-hundred day simple moving average is $20.75. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $30.00. The firm has a market cap of $827.56 million, a PE ratio of -5.31 and a beta of 1.34.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.12. The firm had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. As a group, sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 7,373 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the sale, the insider owned 144,985 shares of the company’s stock, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Paradigm Biocapital Advisors LP lifted its stake in shares of Urogen Pharma by 6.1% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,473,648 shares of the company’s stock valued at $104,773,000 after purchasing an additional 257,564 shares during the period. Morgan Stanley grew its stake in Urogen Pharma by 1.4% in the fourth quarter. Morgan Stanley now owns 2,562,901 shares of the company’s stock worth $60,023,000 after purchasing an additional 34,455 shares during the period. Soleus Capital Management L.P. purchased a new stake in Urogen Pharma in the second quarter worth $29,934,000. SG Americas Securities LLC raised its holdings in Urogen Pharma by 19.0% in the fourth quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock worth $32,264,000 after purchasing an additional 220,264 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in Urogen Pharma in the fourth quarter worth $26,350,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.